Merck's Keytruda Is First Checkpoint Inhibitor To Win US Approval Based On TMB Biomarker

Merck has secured FDA approval for Keytruda for use in tumors with high tumor mutational burden, something Bristol's Opdivo and AstraZeneca's Imfinzi were not able to do in lung cancer.

Athlete in action of high jump.
Keytruda clears a bar for use in TMB-high tumors • Source: Shutterstock

Merck & Co. Inc.'s Keytruda (pembrolizumab) has secured a new tumor-agnostic indication from the US Food and Drug Administration for patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors. Other PD-1/L1 inhibitors, including Bristol-Myers Squibb Co.'s Opdivo (nivolumab) and AstraZeneca PLC's Imfinzi (durvalumab) have both pursued high TMB in lung cancer without success.

The 16 June FDA approval was an accelerated approval based on retrospective analysis of data from 10 cohorts of patients with previously treated unresectable or metastatic solid tumors with TMB-H in KEYNOTE-158; continued approval may be contingent on confirmatory study results

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

 

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.